Heart disease in diabetic patients

Current Diabetes Reports

Volumn 3, Issue 3, 2003, Pages 223-229

  Blendea, Mihaela C ^a   McFarlane, Samy I ^b   Isenovic, Esma R ^b   Gick, Gregory ^b   Sowers, James R ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; BETA CAROTENE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; SELENIUM; SOMATOMEDIN C;

CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DYSLIPIDEMIA; GLUCOSE TOLERANCE TEST; HEART DEATH; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; HEART MUSCLE ISCHEMIA; INCIDENCE; RISK FACTOR;

CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEART FAILURE, CONGESTIVE; HUMANS; INCIDENCE; MYOCARDIAL ISCHEMIA; RISK FACTORS;

EID: 0043022190     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-003-0068-z     Document Type: Review

References (75)

1. Haffner SM, Lehto S, Rönnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infraction. N Engl J Med 1998, 339:229-234.
2. Haffner SM: Coronary heart disease in patients with diabetes. N Engl J Med 2000, 342:1040-1042.
3. Sowers JR, Epstein M, Frolich ED: Diabetes, hypertension and cardiovascular disease: an update. Hypertension 2001, 37:1053-1059.
4. Manson JE, Colditz GA, Stampfer MJ, et al.: A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991, 151:1141-1147.
5. Gustafsson I, Hildebrundt P: Early failure of the diabetic heart. Diabetes Care 2001, 24:3-4.
6. Shindler DM, Kostis JB, Yusuf S, et al.: Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996, 77:1017-1020.
7. Sowers JR: Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998, 158:617-621.
8. Grundy SM, Pasternak R, Greenland P, et al.: AHA/ACC scientific statement: assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 1999, 34:1348-1359.
9. McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713-718.
10. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
11. McFarlane SI, Jacober SJ, Winer N, Sowers JR: Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002, 25:718-723.
12. Rodriguez BL, Lau N, Burchfiel CM, et al.: Glucose intolerance and 23-year risk of coronary heart disease and total mortality. The Honolulu Heart Program. Diabetes Care 1999, 22:1262-1265.
13. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS. UK Prospective Diabetes Study Group [no authors listed]. BMJ 1998, 317:703-713.
14. Assman G, Cullen P, Schulte H: Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 2002, 105:310-315.
15. Intensive blood-glucose controls with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998. 325:837-853.
16. Standl E, Schnell O: A new look at the heart in diabetes mellitus: from ailing to failing. Diabetologia 2000, 43:1455-1469.
17. Malmberg K, Ryden L, Efendic S, et al.: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995, 26:57-65.
18. Risk factors for coronary artery disease in non-insulin dependent diabetes (UKPDS23). UKPDS (United Kingdom Prospective Diabetes Study) Group [no authors listed]. BMJ 1998, 316:823-828.
19. Schannwell CM, Scheppenheim M, Perings S, et al.: Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 2002, 98:33-39.
20. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) [no authors listed]. Lancet 1999, 353:2001-2007.
21. Packer M, Poole-Wilson PA, Armstrong PW, et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999, 100:2312-2318.
22. Kitzman DW, Gardin JM, Gottdiener JS, et al.: Cardiovascular Health Study: importance of heart failure with preserved systolic function in patients Š 65 years of age. Am J Cardiol 2001, 87:413-419.
23. Nilsson G: Diabetes prevalence in acute MI patients. Cardiol Rev 2002, 19:23-25.
24. Grundy SM, Howard B, Smith S Jr, et al.: Prevention Conference VI: Diabetes and Cardiovascular Disease. executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002, 105:2231-2239.
25. Henry P, Thomas F, Benetos A, Guize L: Impaired fasting glucose, blood pressure and cardiovascular mortality. Hypertension 2002, 40:458-463.
26. Sowers JR, Reed J: 1999 Clinical advisory treatment of hypertension and diabetes. J Clin Hypertens 2000, 2:132-133.
27. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998, 351:1755-1762.
28. Tuomilehto J, Rastenyte D, Birkenhager WH, et al.: Effects of calcium channel blockers in older patients with diabetes and systolic hypertension. N Engl J Med 1999, 340:677-684.
29. Fagan TC, Sowers J: Type 2 diabetes mellitus: greater cardiovascular risks and greater benefits of therapy. Arch Intern Med 1999, 24;159:1033-1034.
30. Niskanen L, Hedner T, Hansson L, et al.: Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001, 24:2091-2096.
31. Effects of ramipril on cardiovascular and microvascular out-comes in people with diabetes: results of the HOPE study and Micro-HOPE substudy. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators [no authors listed]. Lancet 2000, 355:253-259.
32. Gall MA, Borch-Johnson K, Hougaard P, et al.: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995, 44:1303-1309.
33. Wei M, Gaskell SP, Haffner SM, Stern MP: Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998, 21:1167-1172.
34. Sniderman AD, Scantlebury T, Cianflone K: Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001, 135:447-459.
35. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. LIPID (Long-Term Intervention with Provastatin in Ischemic Disease) Study Group [no authors listed]. N Engl J Med 1998, 339:1349-1357.
36. McFarlane SI, Muniyappa R, Francisco R, Sowers JR: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002, 87:1451-1458.
37. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. MRC/BHF Heart Protection Study Collaborative Group [no authors listed]. Lancet 2002, 360:7-22.
38. Haffner SM, Alexander CM, Cook TJ, et al.: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: sub-group analysis in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999, 159:2661-2667.
39. Sacks FM, Tonkin AM, Cranen T, et al.: Coronary heart disease in patients with low LDL-cholesterol: benefits of pravastatin in diabetes and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002, 105:1424-1428.
40. Pradhan AD, Ridker PM: Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 2002, 195:1-4
41. Sowers JR: Hypertension, angiotensin II, and oxidative stress. N Engl J Med 2002, 346:1999-2001.
42. Hak AE, Stehouwer CD, Bots ML, et al.: Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Atheroscler Thromb Vasc Biol 1999, 19:1986-1991.
43. Natarjan R, Gerrity RG, Gu J-L, et al.: Role of 12-lipoxygenase and oxidant stress in hyperglycemia-induced acceleration of atherosclerosis in a diabetic pig model. Diabetologia 2002, 45:125-133
44. Aspirin therapy in diabetes (position statement). American Diabetes Association [no authors listed]. Diabetes Care 2000, 23(suppl 1):S61-S62.
45. Francis GS: Diabetic cardiomyopathy: fact or fiction? Heart 2001, 89:247-248.
46. Way KJ, Katai N, King GL: Protein kinase C and the development of diabetic vascular complications. Diabet Med 2001, 18:945-959.
47. Giles TD, Ouyang J, Kerut EK, et al.: Changes in protein kinase C in early cardiomyopathy and in gracilis muscle in the BB/Wor diabetic rat. Am J Physiol Circ Physiol 1998, 43:H295-H307.
48. Duttla K, Podolin DA, Davidson MB, Davidoff Al. Cardiomyocyte dysfunction in sucrose-fed rats is associated with insulin resistance. Diabetes 2001, 50:1186-1192.
49. Cai L, Kang YJ: Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 2001, 1:181-193.
50. Duraisamy Y, Slevin M, Smith N, et al.: Effect of glycation on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: possible relevance to wound healing in diabetes. Angiogenesis 2001, 4:277-288.
51. Huynh NT, Tayek JA: Oral arginine reduces systemic blood pressure in type 2 diabetes: its potential role in nitric oxide generation. J Am Coll Nutr 2002, 21:422-427.
52. Cardillo C, Campia U, Bryant MB, Panza JA:. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 2002, 106:1783-1787.
53. Schneider JG, Tilly N, Hierl T, et al.: Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens 2002, 15:967-972.
54. Aronson D: Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure. Med Hypotheses 2002, 59:297-301.
55. Choi KM, Zhong Y, Hoit BD, et al.: Defective intracellular Ca2+ signaling contributes to cardiomyopathy in type 1 diabetic rats. Am J Physiol Circ Physiol 2002, 283:H1398-H1408.
56. Ren J, Bode AM: Altered cardiac excitation-contraction coupling in ventricular myocytes from spontaneously diabetic BB rats. Am J Physiol Heart Circ Physiol 2000, 279:H238-H244.
57. Grundy SM, Benjamin IJ, Burke GL, et al.: Diabetes and cardiovascular disease. Circulation 1999, 100:1134-1146.
58. Sowers JR, Lester MA: Diabetes and cardiovascular disease. Diabetes Care 1999, 22(suppl 3):C14-C20.
59. Meier-Ewert HK, Nesto RW: Targeting the use of glycoprotein IIb/IIIa antagonists: the diabetic patient. Rev Cardiovasc Med 2002, 3(suppl 1):S20-S27.
60. Ren J, Samson WK, Sewers JR: Insulin-like growth factor 1 as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Moll Cell Cardiol 1999, 31:2049-2061.
61. Peruzzi F, Prisco M, Dews M, et al.: Multiple signaling pathways of the IGF-I receptor in protection from apoptosis. Moll Cell Biol 1999, 19:7203-7215.
62. Frustaci A, Kajstura J, Chimenti C, et al.: Myocardial cell death in human diabetes. Circ Res 2000, 87:1123-1132.
63. Fiordaliso F, Li B, Latini R, et al.: Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent. Lab Invest 2000, 80:513-527.
64. Neumann S, Huse K, Semrau R, et al.: Aldosterone and d-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension 2002, 39:756-760.
65. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic. The BARI Investigators [no authors listed]. J Am Coll Cardiol 2000, 35:1122-1129.
66. Frye RL, Bell MR, Schaff HV, et al.: The role of PCI and CABG in the management of coronary artery disease in patients with diabetes. Curr Diabetes Rep 2002, 2:16-20.
67. Kurbaan AS, Bowker TJ, Ilsley CD, et al.: Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. Am J Coll Cardiol 2001, 87:947-950.
68. Kurbaan AS, Bowker TJ, Ilsley CJ, et al.: The effect of adjusting for baseline risk factors and post revascularization coronary disease on comparisons between coronary angioplasty and bypass surgery. Int J Cardiol 2001, 77:207-214.
69. Niles NW, McGrath P, Malenka D, et al.: Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: Results of a large regional prospective study. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol 2001, 37:1008-1015.
70. Zheng JZ, Croft JB, Giles WH, Mensah GA: Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001, 104:2158-2163.
71. Solini A, Passaro A, D'Elia K, et al.: The relationship of plasma glucose and electrocardiographic parameters in elderly women with different degrees of glucose intolerance. Aging 2000, 12:249-255.
72. Airaksinen KEJ: Silent coronary artery in diabetes - a feature of autonomic neuropathy or accelerated atherosclerosis? Diabetologia 2001, 44:259-266.
73. Schnell O, Hammer K, Muhr-Becker D, et al.: Cardiac sympathetic dysinnervation in type 2 diabetes mellitus with and without ECG-based cardiac autonomic neuropathy. J Diabetes Complications 2002, 16:220-227.
74. Valensi PE, Johnson NB, Maison-Blanche P, et al.: Influence of cardiac autonomic neuropathy on heart rate dependence of ventricular repolarization in diabetic patients. Diabetes Care 2002, 25:918-923.
75. Ren J, Sowers JR, Walsh MF, Brown RA: Reduced contractile response to insulin and IGF-I in ventricular myocytes from genetically obese Zucker rats. Am J Physiol Circ Physiol 2000, 279:H1708-H1714.